drugset / Trial / NCT03549832
Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
RandomizedParallel-groupOpen-labelTreatment
Summary
Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/ paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to prior Sofosbuvir/ Daclatasvir regimens in an open-labeled randomized trial.
Timeline
- Start
- 2018-01-01
- Primary completion
- 2019-01-30
- Completion
- 2019-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daclatasvir | Small molecule | 60 mg | Oral |
| Comparator | Ombitasvir/paritaprevir/ritonavir | Unknown | — | Oral |
| Comparator | Simeprevir | Small molecule | 150 mg | Oral |
| Comparator | Ribavirin | Small molecule | 200 mg | Oral |
| Comparator | Sofosbuvir | Small molecule | 400 mg | Oral |